Ulrich Jaehde
Professor
Research Interests
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
About
Dr. Ulrich Jaehde is an Associate Professor at the University of Bonn in Germany. His research primarily focuses on pharmacology, machine learning in drug therapy, and the safety of medication practices, with recent articles addressing adverse drug reactions and precision dosing. Dr. Jaehde is actively involved in studies related to medication reconciliation and the pharmacokinetics of anticancer drugs, contributing to advancements in patient care and safety.
Articles (22)
Year:
2026
Year:
2026
Year:
2026
Year:
2026
Year:
2026
A variety of classical machine learning (ML) approaches has been developed over the past decade aiming to individualize drug dosages based on measured plasma concentrations. However, the interpretability of these models is challenging as they do not incorporate information on pharmacokinetic (PK) drug disposition. In this work we compare drug plasma concentraton predictions of well‐known population PK (PopPK) modeling with classical machine learning models and a newly proposed scientific machine learning (MMPK‐SciML) framework. MMPK‐SciML allows to estimate PopPK parameters and their inter‐individual variability (IIV) using multimodal covariate data of each patient and does not require assumptions about the underlying covariate relationships. A dataset of 541 fluorouracil (5FU) plasma concentrations as example for an intravenously administered drug and a dataset of 302 sunitinib and its active metabolite concentrations each as example for an orally administered drug were used for analysis. Whereas classical ML models were not able to describe the data sufficiently, MMPK‐SciML allowed us to obtain accurate drug plasma concentration predictions for test patients. In case of 5FU, goodness‐of‐fit shows that the MMPK‐SciML approach predicts drug plasma concentrations more accurately than PopPK models. For sunitinib, we observed slightly less accurate drug concentration predictions compared to PopPK. Overall, MMPK‐SciML has shown promising results and should therefore be further investigated as a valuable alternative to classical PopPK modeling, provided there is sufficient training data.
Year:
2025
Year:
2025
The Medical Informatics Initiative Germany (MII) aims to facilitate the interoperability and exchange of electronic health record data from all German university hospitals. The MII use case “POLyphamacy, drug interActions and Risks” (POLAR_MI) was designed to retrospectively detect medication-related risks in adult inpatients. As part of POLAR_MI, we aimed to build predictive models for specific adverse events. Here, using the two adverse events gastrointestinal bleeding and drug-related hypoglycaemia as examples, we present our initial investigation to determine whether these adverse events and their associations with potential risk factors can be detected. We applied a two-step distributed analysis approach to electronic health record data from 2018 to 2021. This approach consisted of a local statistical data analysis at ten participating centres, followed by a mixed-effects meta-analysis. For each adverse event, two multivariable logistic regression models were constructed: (1) including only demographics, diagnoses and medications, and (2) extended by laboratory values. As numerically stable estimations of both models were not possible at each centre, we constructed different centre subgroups for meta-analyses. We received prevalence estimates of around 1.2% for GI bleeding and around 3.0% for drug-related hypoglycaemia. Although unavailability of laboratory values was a common reason hindering model estimation, multivariable regression models were obtained for both adverse events from several centres. Regarding our original intention to build predictive models, the median area under the receiver operating characteristic curve was above 0.70 for all multivariable regression models, indicating feasibility. In conclusion, plausible estimates for prevalence and regression modelling odds ratios were received when using a distributed analysis approach on inpatient treatment data from diverse German university hospitals. Our results suggest that the development of predictive models in a distributed setting is possible if the research question is adapted to the infrastructure and the available data.
Year:
2025
Adverse drug reactions (ADRs) are a common cause of morbidity and mortality in hospitalized patients. Identification of ADRs in clinical practice, surveillance and research is essential to prevent further harm. The aim of this study was to assess the likelihood of drugs contributing to clinically important inpatient adverse events, in order to provide a list of drug‐event pairs indicating ADRs in electronic health record (EHR) data, referred to as “indicators of ADRs”. We conducted a consensus process based on the RAND/UCLA Appropriateness Method for 14 ADRs. Experts were asked to rate the strength of the causal link between adverse events and potentially causative drugs on a 4‐point Likert scale. Based on the median rating, drug‐event pairs were categorized according to the likelihood of an ADR being present. Drug‐event pairs with a median rating of ≥ 3 without disagreement were defined as indicators of certain and probable ADRs. Of the 255 drug‐event pairs evaluated, 2 (1%) and 42 (16%) achieved consensus validation that they certainly and probably indicate an ADR. In addition, 137 drug‐event pairs were considered as indicators of possible (54%) and 74 drug‐event pairs were considered as indicators of unlikely (29%) ADRs. The provided set of content‐validated indicators of clinically important inpatient ADRs can be used in clinical practice (e.g., decision support), surveillance (e.g., quality indicators) and research (e.g., outcome measures). They will be implemented in EHR data from German university hospitals to determine the prevalence of ADRs, support efficient use of pharmacist resources, and develop models predicting ADRs.
Year:
2025
Drug‐induced hypotension can be harmful and may lead to hospital admissions. The occurrence of hypotension during drug therapy is preventable through increased awareness. This scoping review aimed to provide a comprehensive overview of antihypertensive and nonantihypertensive drugs associated with hypotension in adults. A systematic literature search was conducted using MEDLINE, Embase and Cochrane Library, focusing on studies from January 2013 to May 2023. Search terms were developed to capture key concepts related to hypotension and adverse drug events in adults while excluding terms related to allergic reactions, phytotherapy and studies involving paediatric, pregnant or animal populations. The eligibility criteria included a wide range of study types evaluating hypotension as an adverse drug event across all healthcare settings. Relevant information was extracted from the included studies, while identified drugs associated with hypotension were categorised into drug classes. The review was reported using the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses Extension for Scoping Reviews checklist. In 97 eligible studies, we identified 26 antihypertensive drugs grouped into nine different antihypertensive classes and 158 other drugs grouped into 22 other drug classes. Common antihypertensive classes were angiotensin‐converting enzyme inhibitors, beta blockers and diuretics. Frequently reported nonantihypertensive classes were neuroleptics, alpha‐1 blockers for benign prostatic hyperplasia, benzodiazepines, opioids and antidepressants. The results highlight the importance of healthcare professionals being aware of nonantihypertensive drugs that can cause hypotension. This review provides a basis for future systematic reviews to explore dose‐dependence, drug–drug interactions and confounding factors.
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2025
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2024
Year:
2022
Collaborators (12)
Markus K. Schuler
University Hospital Carl Gustav Carus
Muhammad Bilal
University Hospital Bonn
Stefan Buck
Erasmus MC Cancer Institute
Martin Wiesen
Privatdozent (Associate Professor equiv.) & External Associated Scientist
University of Cologne
Daniel Neumann
Leipzig University
Petra A. Thürmann
Private Universität Witten/Herdecke gGmbH
Axel Heidenreich
-
Silke Gillessen
Full Professor
The University of Manchester
Moritz Ernst
Deputy Head of working group
Institute for Quality and Efficiency in Health Care (IQWiG)
Ron Mathijssen
Full professor
Erasmus University Rotterdam
ANNE WARREN
Associate Lecturer
University of Cambridge
Holger Fröhlich
Full Professor for Biomedical Data Science
University Hospital Bonn
Make your next move.
Prepare your application
Review drafts before you send them.